Frits is an industry veteran with a proven track record in nephrology drug development, including the successful development of Velphoro® and Ferinject® at Vifor Pharma Schlieren / Zurich, Switzerland, 4…
Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer,…
1. What influenced your transition from a career in the pharmaceutical industry to patient advocacy? Professionally, I came to a fork in the road in my career. I took inventory…
1. Can you talk a bit about how your scientific training and industry experience led to your current role at Memo Therapeutics AG? I’m a bioengineer by training, and the…
1. Can you talk a bit about your personal journey in antibody discovery and how this led you to the role at Memo Therapeutics AG MTx ? I’ve had an…
Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy Seasoned commercial leader with significant international experience Joins ahead of lead development candidate potravitug entering Phase III trial Schlieren /…
Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies Schlieren / Zurich,…
Additional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing investors Proceeds will be used to expand Phase II of best-in-class anti-BK…
Appoints Kristie B. Clemmer as VP Clinical Operations and Dr. Maartje Verschuur as VP CMC and Supply Chain Management Schlieren / Zurich, Switzerland, February 5, 2024 – Memo Therapeutics AG…
Mr. van den Berg is an industry veteran with proven track record in building high-performance teams and delivering on strategic and financial transactions Schlieren / Zurich, Switzerland – November 16,…
Series C led by Pureos Bioventures Financing to support completion of a Phase II trial of AntiBKV and to prepare manufacturing of drug for Phase III Schlieren / Zurich, Switzerland…
AntiBKV has potential to be first- and best-in-class treatment representing the sole option for large and growing number of patients Interim data expected by the end of 2023; on track…
